

October 13, 2026

Key Indices Update

Indices	Close	Change (%)
Nifty	22,363.35	0.70↓
Sensex	71,924.68	0.76↓
Midcap	58,834.55	0.08↑
Smallcap	19,425.80	1.42↑

Trend Strength Indicator

Nifty 50 Stocks above 200 EMA	NSE Advance / Decline
5	1795/1796

Key Data

Data	Current	Previous
Dow Jones	51942.85	51852.72
U.S. Dollar Index	102.48	102.13
Brent Crude (USD/ BBL)	105.68	103.22
US 10Y Bond Yield (%)	5.21	5.24
India 10Y Bond Yield (%)	7.39	7.29

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	54773.45	0.87↓
NIFTYAUTO	25015.40	0.63↑
NIFTYENERG	35780.90	0.02↓
NIFTYFINSR	26654.55	0.62↓
NIFTYFMCG	44041.45	1.83↓
NIFTYIT	28234.00	1.19↓
NIFTYMEDIA	1627.45	4.77↑
NIFTYMETAL	11948.75	0.43↓
NIFTYPHARM	26003.50	0.16↑
NIFTYREALT	809.60	0.70↑

Fundamental

Refer Page 02

Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
RELIANCE	Oil & Gas	1,159	1,696	46.3%

*CMP as on October 12 2026

Top News

- ✦ **Dr. Lal PathLabs will invest up to ₹30.3 crore in its wholly owned subsidiary, PathLabs Unifiers (PUPL), through an equity subscription.** The funds will finance PUPL's acquisition of the remaining 30% stake in CentraPath Labs, making CPL its wholly owned subsidiary.
- ✦ **Jubilant Pharmova's Board approved raising up to ₹800 crore through private placement of 80,000 listed, rated, redeemable NCDs of ₹1 lakh each, in one or more tranches, subject to regulatory requirements.**

Technical

Refer Page 03-04

- ✦ **Nifty came under renewed selling pressure on Monday,** giving up early gains and extending the prevailing corrective trend.
- ✦ **After opening on a positive note, the benchmark indices witnessed a sharp reversal** and gradually moved lower as the session progressed.
- ✦ From a technical perspective, **the Nifty is attempting to hold the 22,200–22,400 zone, while 22,550–22,700 is likely to act as the immediate hurdle,** followed by major resistance around 22,900.
- ✦ With volatility elevated and buying conviction remaining weak, **the near-term outlook continues to be cautious.**
- ✦ **We thus reiterate our preference for a hedged approach,** with a negative bias until the index demonstrates sustained strength above key resistance levels.
- ✦ **Stock of the day - NUVAMA**

Fundamental

Top News

01

Dr. Lal PathLabs will invest up to ₹30.3 crore in its wholly owned subsidiary, PUPL, to fund the acquisition of the remaining 30% stake in CentraPath Labs. Post-acquisition, CPL will become PUPL's wholly owned subsidiary.

02

Jubilant Pharmova's Board approved raising up to ₹800 crore through private placement of 80,000 NCDs of ₹1 lakh each, in one or more tranches, subject to applicable laws and regulatory approvals.

03

Greaves Electric Mobility's Ampere added 50+ Experience Centers across 15 states during Navratri, doubling its network to over 600 outlets in just over a year and strengthening its electric scooter sales and service reach.

04

Puravankara signed a JDA for 12.76 acres in North Bengaluru, with a potential GDV of ₹2,500 crore and 1.90 msft saleable area. FY27 additions now total eight projects across key markets, with 12.64 msft development potential and ₹16,600 crore GDV.

05

Pace Digitek's Board approved the issuance of up to 2.5 lakh listed, rated, secured, redeemable NCDs of ₹10,000 each, aggregating ₹250 crore. The debentures are proposed to be listed on BSE's Wholesale Debt Market segment.

Stock for Investment

Reliance Industries Ltd

Stock Symbol	RELIANCE
Sector	Oil & Gas
*CMP (₹)	1,159
^Target Price (₹)	1,696
Upside	46.3%

*CMP as on October 12 2026

^Time horizon - upto 11 Months

- ✦ **Consumer Businesses Drive Growth:** Revenue rose 6.0% YoY, while EBITDA increased 35.7% and PAT surged 76.5%, led by strong Retail, Jio, and O2C performance.
- ✦ **O2C & Digital Fuel Earnings:** Better refining margins, flexible crude sourcing, and growth in 5G, cloud, AI, and enterprise services supported profitability.
- ✦ **Retail & New Energy Expand:** Omnichannel investments and phased commissioning of the Green Energy Giga Complex are expected to drive future growth.
- ✦ **Healthy Outlook; BUY Maintained:** Consumer expansion, O2C recovery, and New Energy investments support long-term earnings growth. BUY | TP: ₹1,696.

Technical

Facing pressure on every bounce. Align positions accordingly.

NIFTY

22363.35 ▼ 157.10 (0.70%)

S1

22200

S2

22000


R1

22500

R2

22650

Technical Chart : Daily



- ✦ **Nifty came under renewed selling pressure on Monday**, giving up early gains and extending the prevailing corrective trend.
- ✦ **After opening on a positive note, the benchmark indices witnessed a sharp reversal** and gradually moved lower as the session progressed.
- ✦ From a technical perspective, **the Nifty is attempting to hold the 22,200–22,400 zone**, while **22,550–22,700 is likely to act as the immediate hurdle**, followed by major resistance around 22,900.
- ✦ **We thus reiterate our preference for a hedged approach**, with a negative bias until the index demonstrates sustained strength above key resistance levels.

BANKNIFTY

54918.00 ▼ 338.65 (0.61%)

S1

54400

S2

53800


R1

55400

R2

55800

Technical Chart : Daily



- ✦ **The banking index witnessed profit booking on Monday** after the previous session's strength, encountering resistance near the 20 DEMA.
- ✦ **Despite a sideways opening, persistent selling pressure dominated the session**, keeping the index biased to the downside.
- ✦ **Sectoral participation remained broadly weak**, with Kotak Bank demonstrating relative resilience, while SBI and IndusInd Bank led the decline.
- ✦ **Immediate resistance is positioned near 55,800**, while **crucial downside support emerges around 53,800**.

Technical

Stock of the day

NUVAMA

Recom.

BUY

CMP (₹)

1868.8

Range*

1860-1870

SL

1795

Target

2010

Technical Chart : Daily



- ✦ **NUVAMA is demonstrating bullish continuation, supported by an upside breakout** from consolidation and a sustained higher-high, higher-low structure.
- ✦ **The stock has decisively breached its descending trendline and reclaimed the 20-day EMA**, signalling strengthening momentum.
- ✦ **Expanding volumes during up-moves indicates renewed buying interest** and reinforce the positive technical outlook.
- ✦ **Traders may consider accumulating the stock** within the recommended range.

Momentum Stocks Midcap

Name	Price	Price %
NIACL	184.45	13.70↑
TRIVENI	251.69	6.80↑
BRIGADE	577.65	5.26↑
SUMICHEM	416.75	0.13↓
GSPL	268.35	7.13↓

Name	Price	Price %
PNBHousing	1199.70	3.60↑
RELIANCE	1153.80	1.41↓
COALINDIA	403.95	1.85↓
GMRAIRPORT	89.45	3.10↓
TECHM	1466.40	3.15↓

Range Breakout/Breakdown

Top 5 F&O Gainers

Name	Price	Price %
UPL	513.85	5.20↑
SUZLON	39.33	4.60↑
TATAELXSI	3255.50	4.01↑
ANGELONE	303.15	3.82↑
IRFC	77.42	3.64↑

Name	Price	Price %
DMART	3359.00	4.49↓
FORTIS	756.10	3.83↓
DABUR	373.80	3.34↓
ITC	257.20	3.31↓
APOLLOHOSP	7772.50	3.18↓

Top 5 F&O Losers

Bullish Charts

Name	Price	Price %
DELHIVERY	412.00	2.87↑
DRREDDY	1232.40	2.96↑
KFINTECH	865.10	2.70↑
PNBHousing	1199.70	3.60↑
POLICYBZR	1047.10	3.47↑

Name	Price	Price %
AMBUJACEM	343.45	2.29↓
COLPAL	1775.40	2.33↓
GMRAIRPORT	89.45	3.10↓
MAXHEALTH	857.40	2.99↓
TECHM	1466.40	3.15↓

Bearish Charts

Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Rajan Gupta	rajan.gupta1@religare.com
Vivek Chandra	vivek.chandra@religare.com
Himanshu Gupta	himanshu.gupta1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes: Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results

